Zacks Investment Research downgraded shares of Xencor (NASDAQ:XNCR) from a hold rating to a sell rating in a research report sent to investors on Thursday, March 8th.
According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “
A number of other analysts also recently weighed in on XNCR. Piper Jaffray Companies restated a buy rating and issued a $35.00 price target on shares of Xencor in a research note on Sunday, November 12th. Cantor Fitzgerald initiated coverage on Xencor in a research note on Wednesday, November 29th. They issued an overweight rating and a $33.00 price target on the stock. Finally, BidaskClub upgraded Xencor from a strong sell rating to a sell rating in a research note on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $34.25.
Shares of Xencor (NASDAQ XNCR) opened at $30.88 on Thursday. Xencor has a 12 month low of $18.55 and a 12 month high of $34.63. The firm has a market capitalization of $1,467.18, a P/E ratio of -29.69 and a beta of 1.50.
In other Xencor news, insider Paul A. Foster sold 10,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $26.03, for a total transaction of $260,300.00. Following the sale, the insider now directly owns 12,419 shares in the company, valued at $323,266.57. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Edgardo Baracchini, Jr. sold 40,000 shares of the business’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $30.89, for a total value of $1,235,600.00. Following the sale, the insider now owns 40,000 shares in the company, valued at $1,235,600. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,000 shares of company stock worth $3,101,550. Company insiders own 4.03% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. MetLife Investment Advisors LLC purchased a new stake in Xencor during the fourth quarter worth $365,000. Redmile Group LLC boosted its position in Xencor by 12.5% during the fourth quarter. Redmile Group LLC now owns 1,350,894 shares of the biopharmaceutical company’s stock worth $29,612,000 after purchasing an additional 150,600 shares in the last quarter. Macquarie Group Ltd. boosted its position in Xencor by 73.9% during the fourth quarter. Macquarie Group Ltd. now owns 95,643 shares of the biopharmaceutical company’s stock worth $2,096,000 after purchasing an additional 40,643 shares in the last quarter. Vident Investment Advisory LLC boosted its position in Xencor by 5.9% during the fourth quarter. Vident Investment Advisory LLC now owns 59,426 shares of the biopharmaceutical company’s stock worth $1,303,000 after purchasing an additional 3,289 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Xencor during the fourth quarter worth $1,456,000. Institutional investors own 79.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Xencor (NASDAQ:XNCR) Rating Lowered to Sell at Zacks Investment Research” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/18/xencor-xncr-rating-lowered-to-sell-at-zacks-investment-research.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Get a free copy of the Zacks research report on Xencor (XNCR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.